Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia

Journal of Urology

Volumn 159, Issue 6, 1998, Pages 1810-1815

  Kyprianou, Natasha ^a   Litvak, Juan P ^a   Borkowski, Andrew ^a   Alexander, Richard ^a   Jacobs, Stephen C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Doxazosin; Prostate

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN;

ADRENERGIC RECEPTOR BLOCKING; ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATE HYPERTROPHY; SMOOTH MUSCLE; TREATMENT OUTCOME;

EID: 0032426688     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63162-8     Document Type: Article

References (34)

1. Walsh, P. C.: Benign prostatic hyperplasia: etiological considerations. In: Approaches to the Study of Benign Prostatic Hyperplasia. Edited by F. A. Kimball, A. E. Buhl and A. E. Carter. New York: Liss, pp.10-25, 1984.
2. Oesterling, J. E.: Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate, suppl., 6: 67, 1996.
3. Berry, S. J., Coffey, D. S. Walsh, P. C. and Ewing, L. L.: The development of human benign prostatic hyperplasia with age. J. Urol., 132: 474, 1984.
4. Isaacs J. T. and Coffey, D. S.: Etiology and disease process of benign prostatic hyperplasia. Prostate, suppl., 2: 33, 1989.
5. Caine, M., Pfau, A. and Perlberg, S.: The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol., 48: 255, 1976.
6. Caine, M., Raz, S. and Ziegler, M.: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Brit. J. Urol., 47: 193, 1975.
7. McConnell, J. D.: Medical management of benign prostatic hyperplasia with androgen suppression. Prostate, suppl., 3: 49, 1990.
8. Lepor, H.: Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol. Clin. N. Amer., 17: 651, 1990.
9. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B. and Ng, J.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. J. Med., 327: 1185, 1992.
10. Peters, C. A. and Walsh, P. C.: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New Engl. J. Med., 317: 599, 1987.
11. Lepor, H., Tang, R. and Shapiro, E.: The alpha-adrenerecptor subtype mediating the tension of human prostatic smooth muscle. Prostate, 22: 301, 1993.
12. Lepor, H.: Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate, suppl., 3: 75, 1990.
13. Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol., 154: 105, 1995.
14. Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K. and Dias, N. for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose response multicenter study. J. Urol., 154: 110, 1995.
15. Arrends, M. J. and Wyllie, A. H.: Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Path., 32: 233, 1991.
16. Berges, R. R., Vucanovic, J., Epstein, J. I., Carmichael, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C. and Isaacs, J. T.: Implication of cell cycle kinetic changes during the progression of human prostate cancer. Clin. Cancer Res., 1: 473, 1995.
17. Kyprianou, N., Tu, H. and Jacobs, S. C.: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Path., 27: 668, 1996.
18. Hockenberry, D. M., Zutler, M., Hickey, N., Nahm, M. and Korsmeyer, S. J.: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci., 88: 6961, 1991.
19. McNeal, J. E.: Pathology of benign prostatic hyperplasia: insight into etiology. Urol. Clin. N. Amer., 17: 477, 1990.
20. Walsh, P. C.: Benign prostatic hyperplasia. In: Campbell's Urology, 6th ed. Edited by P. C. Walsh, A. B. Retik, T. A. Stamey and E. D. Vaughan, Jr. Philadelphia: W. B. Saunders Co., pp. 1009-1023, 1992.
21. Skalli, O., Ropraz, P., Treciak, A., Benzonana, G., Gillesen, D. and Gabbiani, G.: A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell. Biol., 103: 2787, 1986.
22. Zhang, J., Hess, M. W., Thurnher, M., Hobisch, A., Radmayr, C., Cronauer, M. V., Hittmair, A., Culig. Z., Bartch, G. and Klocker, H.: Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Prostate, 30: 117, 1997.
23. Altmannsberger, M., Osborn, M., Schauer, A. and Weber, K.: Antibodies to different intermediate filament proteins. Cell type specific markers on parrafin-embedded human tissue. Lab. Invest., 45: 427, 1981.
24. Shapiro, E., Hartanto, V. and Lepor, H.: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J. Urol., 147: 1167, 1992.
25. Shapiro, E., Hartanto, V. and Lepor, H.: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate, 21: 297, 1992.
26. Yang, G., Timme, T. L., Park, S. H., Wu, X., Wyllie, M. G. and Thompson, T. C.: Transforming growth factor β1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate, 33: 157, 1997.
27. Andersson, K. E., Lepor, H. and Wyllie, M. G.: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate, 30: 202, 1997.
28. Lepor, H. and Shapiro, E.: Characterization of alphal adrenergic receptors in human benign prostatic hyperplasia. J. Urol., 132: 1226, 1984.
29. Price, D. T., Schwin, D. A., Lomasney, J. W., Allen, L. F., Caron, M. G. and Lefkowitz, R. J.: Identification, quantification and localization of mRNA for three distinct alphal adrenergic receptor subtypes in human prostate. J. Urol., 150: 546, 1993.
30. Price, H., McNeal, J. E. and Stamey, T. A.: Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Path., 21: 578, 1990.
31. Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P. and Padley, R. J.: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med., 335: 533, 1996.
32. Kyprianou, N. and Isaacs, J. T.: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology, 122: 552, 1988.
33. Lamb, J. C., English, H., Levandoski, P. L., Rhodes, G. R., Johnson, R. K. and Isaacs, J. T.: Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology, 130: 685, 1992.
34. Rittmaster, R. S., Manning, A. P., Wright, A. S., Thomas, L. N., Whitefield, S., Norman, R. W., Lazier, C. B. and Rowden, G.: Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology, 136: 741, 1995.